CPC Scientific selects Rocklin for manufacturing facility

Facility at Atherton Business Park

Rocklin, Calif. – CPC Scientific Inc., a leading global synthetic peptide production company that helps bring life changing therapeutics and diagnostics to market, has chosen Rocklin, CA, as the location of its new U.S.-based manufacturing site. The company will initially bring with them up to 50 high-quality life-science and manufacturing jobs.

The 41,000 sq. ft. facility in the Atherton Business Park will be utilized to manufacture clinical and commercial grade peptide products, increasing CPC Scientific’s manufacturing capacity and diversifying their supply chain. (WebMD: What Are Peptides?)

“CPC has helped many of our clients to bring an innovative drug into the market from a concept,” said Shawn Lee, PhD, CEO. “With the new Rocklin site, we believe we will be able to contribute more, especially to the Northern American market, using our decades of peptide synthesis expertise to help our clients save lives and improve human health worldwide.”

Peptide-based therapeutic candidates

Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years.

For over two decades, CPC Scientific has been a reliable partner for their clients all over the world, including multinational pharmaceutical companies, biotech companies and academic institutions, by providing value-added one-stop-shop development and manufacturing services to support their clinical trials.

Fully operational in 2023

“The science may be complicated, but it’s easy to understand how this life-science leader can help build this industry cluster in the region and attract more companies and high paying jobs,” Rocklin Mayor Bill Halldin said. “We have enjoyed getting to know the CPC Scientific leadership as they finalized their choice of Rocklin and look forward to their continued success in biotechnology and life-sciences.”
The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023.

With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.